Regulator of G-protein signaling-5 induction in pericytes coincides with active vessel remodeling during neovascularization

被引:160
作者
Berger, M
Bergers, G
Arnold, B
Hämmerling, GJ
Ganss, R
机构
[1] German Canc Res Ctr, Dept Mol Immunol, D-69120 Heidelberg, Germany
[2] Univ Calif San Francisco, Ctr Comprehens Canc, BTRC, Dept Neurol Surg, San Francisco, CA 94143 USA
关键词
D O I
10.1182/blood-2004-06-2315
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We identified regulator of G-protein signaling-5 (RGS-5) as an angiogenic pericyte marker at sites of physiologic and pathologic angiogenesis. In a mouse model of pancreatic islet cell carcinogenesis, RGS-5 is specifically induced in the vasculature of premalignant lesions during the "angiogenic switch" and further elevated in tumor vessels. Similarly, RGS-5 is over-expressed in highly angiogenic astrocytomas but not in hypoxia-inducible factor-1alpha (HIF-1alpha)-deficient tumors, which grow along preexisting brain capillaries without inducing neovessels. Elevated levels of RGS-5 in pericytes are also observed during wound healing and ovulation indicating a strong correlation between RGS-5 expression and active vessel remodeling beyond tumor angiogenesis. Moreover, antitumor therapy, which reverses tumor vasculature to an almost normal morphology, results in down-regulation of RGS-5 transcription. Taken together, these data demonstrate for the first time a factor that is specific for "activated" pericytes. This further supports the notion that pericytes, like endothelial cells, undergo molecular changes during neovascularization that makes them a novel target for antiangiogenic therapy. (C) 2005 by The American Society of Hematology.
引用
收藏
页码:1094 / 1101
页数:8
相关论文
共 42 条
[1]  
Bell SE, 2001, J CELL SCI, V114, P2755
[2]   Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal [J].
Benjamin, LE ;
Golijanin, D ;
Itin, A ;
Pode, D ;
Keshet, E .
JOURNAL OF CLINICAL INVESTIGATION, 1999, 103 (02) :159-165
[3]  
Benjamin LE, 1998, DEVELOPMENT, V125, P1591
[4]   Tumorigenesis and the angiogenic switch [J].
Bergers, G ;
Benjamin, LE .
NATURE REVIEWS CANCER, 2003, 3 (06) :401-410
[5]   Effects of angiogenesis inhibitors on multistage carcinogenesis in mice [J].
Bergers, G ;
Javaherian, K ;
Lo, KM ;
Folkman, J ;
Hanahan, D .
SCIENCE, 1999, 284 (5415) :808-812
[6]   Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors [J].
Bergers, G ;
Song, S ;
Meyer-Morse, N ;
Bergsland, E ;
Hanahan, D .
JOURNAL OF CLINICAL INVESTIGATION, 2003, 111 (09) :1287-1295
[7]   The hypoxic response of tumors is dependent on their microenvironment [J].
Blouw, B ;
Song, HQ ;
Tihan, T ;
Bosze, J ;
Ferrara, N ;
Gerber, HP ;
Johnson, RS ;
Bergers, G .
CANCER CELL, 2003, 4 (02) :133-146
[8]   Transcription profiling of platelet-derived growth factor-B-deficient mouse embryos identifies RGS5 as a novel marker for pericytes and vascular smooth muscle cells [J].
Bondjers, C ;
Kalén, M ;
Hellström, M ;
Scheidl, SJ ;
Abramsson, A ;
Renner, O ;
Lindahl, P ;
Cho, HS ;
Kehrl, J ;
Betsholtz, C .
AMERICAN JOURNAL OF PATHOLOGY, 2003, 162 (03) :721-729
[9]   Regulation of chemotactic and proadhesive responses to chemoattractant receptors by RGS (Regulator of G-protein Signaling) family members [J].
Bowman, EP ;
Campbell, JJ ;
Druey, KM ;
Scheschonka, A ;
Kehrl, JH ;
Butcher, EC .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (43) :28040-28048
[10]  
Carson-Walter EB, 2001, CANCER RES, V61, P6649